Drug Development
DURECT Corporation announces positive Phase I study results with new pain product in development
Published in Drug Week, January 12th, 2007
We believe that the persistent pain market remains underserved and that DUR-843 has the potential to provide several advantages over existing pain medications.
"We are pleased to add another product candidate to our pipeline and with the rapid progress and positive results thus far," stated James E. Brown, DVM, president and CEO of DURECT. "As a result of our recent collaboration with Nycomed covering POSIDUR, we are in a stronger financial position and therefore have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-01-12)
More Articles from Drug Week
- Drug Development
Peregrine, Biotecnol develop immunocytokine fusion proteins for cancer and anti-viral indications - Allergies Therapy
Research on allergies therapy discussed by scientists at University of Helsinki, Faculty of Pharmacy - Anaphylactic Shock Therapy
Researchers at State University of New York have published new data on anaphylactic shock therapy - Aneurysm Therapy
Study data from University Hospital update understanding of aneurysm therapy - Anti-Infectives
Research data from PLA General Hospital, Department of Clinical Pharmacology update understanding of anti-infectives - Anti-Infectives
Research from Cubist Pharmaceuticals in anti-infectives provides new insights - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
